Grant of options
London, UK - 04 October 2023: Oxford Biomedica plc ("Oxford Biomedica" or "the Company") (LSE: OXB) announces that on 04 October 2023 nil-cost share options over ordinary shares of 50 pence each in the Company were granted under the Oxford Biomedica 2015 Deferred Bonus Plan ("DBP") and the Oxford Biomedica 2015 Long Term Incentive Plan ("LTIP").
2023 LTIP and 2022 DBP Awards
| Name of individual | Title | Number of shares subject to the 2022 DBP award | Number of shares subject to the 2023 LTIP award | Total shares over which options now held | Percentage of current issued share capital under option |
| Frank Mathias | Chief Executive Officer | - | 323,178 | 323,178 | 0.334% |
| Stuart Paynter | Chief Financial Officer | 63,869 | 142,469 | 538,211 | 0.556% |
| Sebastien Ribault | Chief Commercial Officer | | 66,903 | 66,903 | 0.069% |
| Mark Caswell | Site Head US Operations | | 74,172 | 74,172 | 0.077% |
| Lisa James | Chief People Officer | 15,887 | 39,670 | 99,989 | 0.103% |
| James Miskin | Chief Technical Officer | 32,189 | 56,262 | 215,035 | 0.222% |
| Kyriacos Mitrophanous | Chief Scientific Officer | 35,256 | 57,906 | 277,856 | 0.287% |
| Madduri Ravi Rao | Chief Medical Officer | 21,129 | 50,135 | 131,400 | 0.136% |
| Matthew Treagus | Chief Information Officer and Chief of Staff | 32,468 | 54,433 | 143,648 | 0.148% |
| Natalie Walter | General Counsel | 27,897 | 48,069 | 167,244 | 0.173% |
Under the terms of the DBP plan, the DBP awards will become exercisable as to one third of the shares subject to each award on each of the first three anniversaries of the grant date.
In line with best practice and current investor guidance the quantum of the 2023 LTIP to Frank Mathias was scaled back from 200% of salary to 160% of salary and for Stuart Paynter the quantum of the 2023 LTIP was scaled back by 30% from 175% of salary to 122.5% of salary. The quantum of 2023 LTIP granted to other new members of SET was scaled back by 20%, all other members of the set had their awards scaled back by 30%
The LTIP awards are subject to performance conditions. As set out in the 2022 Directors' Remuneration Report, the performance condition is based on TSR (40% of the award, assessed over the three years from grant); revenue growth (40% of the award, assessed over financial years 2023, 2024 and 2025) and strategic milestones (20% of the award). Details of the measures are included in the 2022 Directors' Remuneration Report, other than as regards the strategic milestones, which are commercially sensitive and will be disclosed in due course.
The LTIP awards granted to Frank Mathias and Stuart Paynter will "vest" following the assessment of the performance condition, but will only be "released" so that they can be exercised following the end of a further two year holding period. The 2023 awards granted to other participants will vest and be released following the assessment of the performance condition.
The Notification of Dealing Forms set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.
Notification of Dealing Form
| 1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | |||||
| a) | Name | Frank Mathias | ||||
| 2. | Reason for the notification | |||||
| a) | Position/status | Chief Executive Officer
| ||||
| b) | Initial notification/ amendment | Initial Notification | ||||
| 3. | Details of the Issuer | |||||
| a) | Name | Oxford Biomedica plc | ||||
| b) | LEI code | 213800S1GVQNXQ15K851 | ||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument
Identification code | Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 | ||||
| b) | Nature of the transaction | Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards. | ||||
| c) | Price(s) and volumes(s) | 2023 LTIP Award
| ||||
| d) | Aggregated information - Aggregate volume
- Price
|
Awards granted over 323,178 shares in total
N/A
| ||||
| e) | Date of the transaction | 2023-10-04 | ||||
| f) | Place of the transaction | Outside of trading venue | ||||
| 1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | |||||||||
| a) | Name | Stuart Paynter | ||||||||
| 2. | Reason for the notification | |||||||||
| a) | Position/status | Chief Financial Officer
| ||||||||
| b) | Initial notification/ amendment | Initial Notification | ||||||||
| 3. | Details of the Issuer | |||||||||
| a) | Name | Oxford Biomedica plc | ||||||||
| b) | LEI code | 213800S1GVQNXQ15K851 | ||||||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||
| a) | Description of the financial instrument
Identification code | Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 | ||||||||
| b) | Nature of the transaction | Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan and Deferred Bonus Plan. No consideration was paid for the grant of awards. | ||||||||
| c) | Price(s) and volumes(s) | 2023 LTIP Award
2022 DBP Award
| ||||||||
| d) | Aggregated information - Aggregate volume
- Price
|
Awards granted over 206,338 shares in total
N/A
| ||||||||
| e) | Date of the transaction | 2023-10-04 | ||||||||
| f) | Place of the transaction | Outside of trading venue | ||||||||
| 1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | |||||
| a) | Name | Sebastien Ribault | ||||
| 2. | Reason for the notification | |||||
| a) | Position/status | Chief Commercial Officer | ||||
| b) | Initial notification/ amendment | Initial Notification | ||||
| 3. | Details of the Issuer | |||||
| a) | Name | Oxford Biomedica plc | ||||
| b) | LEI code | 213800S1GVQNXQ15K851 | ||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument
Identification code | Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 | ||||
| b) | Nature of the transaction | Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards. | ||||
| c) | Price(s) and volumes(s) | 2023 LTIP Award
| ||||
| d) | Aggregated information - Aggregate volume
- Price
|
Awards granted over 66,903 shares in total
N/A
| ||||
| e) | Date of the transaction | 2023-10-04 | ||||
| f) | Place of the transaction | Outside of trading venue | ||||
| 1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | |||||
| a) | Name | Mark Caswell | ||||
| 2. | Reason for the notification | |||||
| a) | Position/status | Site Head of US Operations | ||||
| b) | Initial notification/ amendment | Initial Notification | ||||
| 3. | Details of the Issuer | |||||
| a) | Name | Oxford Biomedica plc | ||||
| b) | LEI code | 213800S1GVQNXQ15K851 | ||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument
Identification code | Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 | ||||
| b) | Nature of the transaction | Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards. | ||||
| c) | Price(s) and volumes(s) | 2023 LTIP Award
| ||||
| d) | Aggregated information - Aggregate volume
- Price
|
Awards granted over 74,172 shares in total
N/A
| ||||
| e) | Date of the transaction | 2023-10-04 | ||||
| f) | Place of the transaction | Outside of trading venue | ||||
| 1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | |||||||||
| a) | Name | Lisa James | ||||||||
| 2. | Reason for the notification | |||||||||
| a) | Position/status | Chief People Officer | ||||||||
| b) | Initial notification/ amendment | Initial Notification | ||||||||
| 3. | Details of the Issuer | |||||||||
| a) | Name | Oxford Biomedica plc | ||||||||
| b) | LEI code | 213800S1GVQNXQ15K851 | ||||||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||
| a) | Description of the financial instrument
Identification code | Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 | ||||||||
| b) | Nature of the transaction | Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan and Deferred Bonus Plan. No consideration was paid for the grant of awards. | ||||||||
| c) | Price(s) and volumes(s) | 2023 LTIP Award
2022 DBP Award
| ||||||||
| d) | Aggregated information - Aggregate volume
- Price
|
Awards granted over 55,557 shares in total
N/A
| ||||||||
| e) | Date of the transaction | 2023-10-04 | ||||||||
| f) | Place of the transaction | Outside of trading venue | ||||||||
| 1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | |||||||||
| a) | Name | James Miskin | ||||||||
| 2. | Reason for the notification | |||||||||
| a) | Position/status | Chief Technical Officer | ||||||||
| b) | Initial notification/ amendment | Initial Notification | ||||||||
| 3. | Details of the Issuer | |||||||||
| a) | Name | Oxford Biomedica plc | ||||||||
| b) | LEI code | 213800S1GVQNXQ15K851 | ||||||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||
| a) | Description of the financial instrument
Identification code | Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 | ||||||||
| b) | Nature of the transaction | Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan and Deferred Bonus Plan. No consideration was paid for the grant of awards. | ||||||||
| c) | Price(s) and volumes(s) | 2023 LTIP Award
2022 DBP Award
| ||||||||
| d) | Aggregated information - Aggregate volume
- Price
|
Awards granted over 88,451 shares in total
N/A
| ||||||||
| e) | Date of the transaction | 2023-10-04 | ||||||||
| f) | Place of the transaction | Outside of trading venue | ||||||||
| 1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | |||||||||
| a) | Name | Kyriacos Mitrophanous | ||||||||
| 2. | Reason for the notification | |||||||||
| a) | Position/status | Chief Scientific Officer | ||||||||
| b) | Initial notification/ amendment | Initial Notification | ||||||||
| 3. | Details of the Issuer | |||||||||
| a) | Name | Oxford Biomedica plc | ||||||||
| b) | LEI code | 213800S1GVQNXQ15K851 | ||||||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||
| a) | Description of the financial instrument
Identification code | Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 | ||||||||
| b) | Nature of the transaction | Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan and Deferred Bonus Plan. No consideration was paid for the grant of awards. | ||||||||
| c) | Price(s) and volumes(s) | 2023 LTIP Award
2022 DBP Award
| ||||||||
| d) | Aggregated information - Aggregate volume
- Price
|
Awards granted over 93,162 shares in total
N/A
| ||||||||
| e) | Date of the transaction | 2023-10-04 | ||||||||
| f) | Place of the transaction | Outside of trading venue | ||||||||
| 1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | |||||||||
| a) | Name | Madduri Rao | ||||||||
| 2. | Reason for the notification | |||||||||
| a) | Position/status | Chief Medical Officer | ||||||||
| b) | Initial notification/ amendment | Initial Notification | ||||||||
| 3. | Details of the Issuer | |||||||||
| a) | Name | Oxford Biomedica plc | ||||||||
| b) | LEI code | 213800S1GVQNXQ15K851 | ||||||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||
| a) | Description of the financial instrument
Identification code | Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 | ||||||||
| b) | Nature of the transaction | Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan and Deferred Bonus Plan. No consideration was paid for the grant of awards.
| ||||||||
| c) | Price(s) and volumes(s) | 2023 LTIP Award
2022 DBP Award
| ||||||||
| d) | Aggregated information - Aggregate volume
- Price
|
Awards granted over 71,264 shares in total
N/A
| ||||||||
| e) | Date of the transaction | 2023-10-04 | ||||||||
| f) | Place of the transaction | Outside of trading venue | ||||||||
| 1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | |||||||||
| a) | Name | Matthew Treagus | ||||||||
| 2. | Reason for the notification | |||||||||
| a) | Position/status | Chief Information Officer and Chief of Staff | ||||||||
| b) | Initial notification/ amendment | Initial Notification | ||||||||
| 3. | Details of the Issuer | |||||||||
| a) | Name | Oxford Biomedica plc | ||||||||
| b) | LEI code | 213800S1GVQNXQ15K851 | ||||||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||
| a) | Description of the financial instrument
Identification code | Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 | ||||||||
| b) | Nature of the transaction | Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan and Deferred Bonus Plan. No consideration was paid for the grant of awards. | ||||||||
| c) | Price(s) and volumes(s) | 2023 LTIP Award
2022 DBP Award
| ||||||||
| d) | Aggregated information - Aggregate volume
- Price
|
Awards granted over 86,901 shares in total
N/A
| ||||||||
| e) | Date of the transaction | 2023-10-04 | ||||||||
| f) | Place of the transaction | Outside of trading venue | ||||||||
| 1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | |||||||||
| a) | Name | Natalie Walter | ||||||||
| 2. | Reason for the notification | |||||||||
| a) | Position/status | General Counsel | ||||||||
| b) | Initial notification/ amendment | Initial Notification | ||||||||
| 3. | Details of the Issuer | |||||||||
| a) | Name | Oxford Biomedica plc | ||||||||
| b) | LEI code | 213800S1GVQNXQ15K851 | ||||||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||
| a) | Description of the financial instrument
Identification code | Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 | ||||||||
| b) | Nature of the transaction | Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan and Deferred Bonus Plan. No consideration was paid for the grant of awards. | ||||||||
| c) | Price(s) and volumes(s) | 2023 LTIP Award
2022 DBP Award
| ||||||||
| d) | Aggregated information - Aggregate volume
- Price
|
Awards granted over 75,966 shares in total
N/A
| ||||||||
| e) | Date of the transaction | 2023-10-04 | ||||||||
| f) | Place of the transaction | Outside of trading venue | ||||||||
-Ends-
| For further information, please contact: | |
|
Oxford Biomedica plc: Natalie Walter, Company Secretary |
Tel: +44 (0)1865 783 000 |
About Oxford Biomedica
Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.
Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK and near Boston, MA, US. Learn more at www.oxb.com, www.oxbsolutions.com, and follow us on LinkedIn and YouTube.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
